Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Oddens J., Brausi M., Sylvester R., Bono A., van de Beek C., van Andel G., ...More

EUROPEAN UROLOGY, vol.63, no.3, pp.462-472, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 63 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.1016/j.eururo.2012.10.039
  • Title of Journal : EUROPEAN UROLOGY
  • Page Numbers: pp.462-472
  • Keywords: Non-muscle invasive bladder cancer, Randomized Controlled Trial, Immunotherapy, Bacillus Calmette-Guerin, Adjuvant treatment, Urinary bladder, Maintenance therapy, TRANSITIONAL-CELL CARCINOMA, TRANSURETHRAL RESECTION, UROTHELIAL CARCINOMA, MITOMYCIN-C, FOLLOW-UP, 27 MG, TRIAL, TUMORS, PROGRESSION, EFFICACY


Background: The optimal dose and duration of intravesical bacillus Calmette-Guerin (BCG) in the treatment of non-muscle-invasive bladder cancer (NMIBC) are controversial.